Myriad Genetics Inc. said the Medicare Administrative Contractor Palmetto GBA MolDx has issued a final local coverage determination for the myPath Melanoma test to help physicians provide a definitive diagnosis when a suspicious skin lesion is equivocal based upon histopathology.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
